Diversified Trust Co Increases Stock Holdings in CVS Health Corporation $CVS

Diversified Trust Co lifted its stake in CVS Health Corporation (NYSE:CVS) by 69.3% in the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 7,370 shares of the pharmacy operator’s stock after purchasing an additional 3,018 shares during the quarter. Diversified Trust Co’s holdings in CVS Health were worth $508,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Vanguard Group Inc. boosted its holdings in shares of CVS Health by 0.8% in the 1st quarter. Vanguard Group Inc. now owns 118,335,394 shares of the pharmacy operator’s stock worth $8,017,223,000 after purchasing an additional 969,027 shares during the period. Dodge & Cox boosted its holdings in shares of CVS Health by 4.8% in the 1st quarter. Dodge & Cox now owns 73,459,122 shares of the pharmacy operator’s stock worth $4,976,856,000 after purchasing an additional 3,353,223 shares during the period. Invesco Ltd. boosted its holdings in shares of CVS Health by 13.2% in the 1st quarter. Invesco Ltd. now owns 20,413,853 shares of the pharmacy operator’s stock worth $1,383,039,000 after purchasing an additional 2,375,764 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in shares of CVS Health by 14.5% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 15,309,289 shares of the pharmacy operator’s stock worth $1,037,205,000 after purchasing an additional 1,942,886 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of CVS Health by 5.6% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 13,647,873 shares of the pharmacy operator’s stock worth $924,643,000 after purchasing an additional 728,924 shares during the period. Hedge funds and other institutional investors own 80.66% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on CVS. UBS Group upgraded CVS Health from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $67.00 to $79.00 in a report on Monday, August 18th. Morgan Stanley boosted their price objective on CVS Health from $80.00 to $82.00 and gave the company an “overweight” rating in a report on Friday, August 1st. Wolfe Research boosted their price objective on CVS Health from $80.00 to $85.00 and gave the company an “outperform” rating in a report on Monday. Robert W. Baird upgraded CVS Health from a “neutral” rating to an “outperform” rating and boosted their price objective for the company from $71.00 to $82.00 in a report on Thursday, August 14th. Finally, Zacks Research cut CVS Health from a “strong-buy” rating to a “hold” rating in a report on Monday, September 8th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $78.25.

CVS Health Trading Up 1.7%

Shares of NYSE CVS opened at $76.44 on Wednesday. The company has a quick ratio of 0.62, a current ratio of 0.80 and a debt-to-equity ratio of 0.74. The business has a fifty day simple moving average of $68.38 and a two-hundred day simple moving average of $66.77. The firm has a market cap of $96.96 billion, a PE ratio of 21.35, a price-to-earnings-growth ratio of 0.83 and a beta of 0.62. CVS Health Corporation has a twelve month low of $43.56 and a twelve month high of $76.92.

CVS Health (NYSE:CVS) last issued its earnings results on Thursday, July 31st. The pharmacy operator reported $1.81 earnings per share for the quarter, beating analysts’ consensus estimates of $1.46 by $0.35. The business had revenue of $98.92 billion during the quarter, compared to analyst estimates of $94.87 billion. CVS Health had a return on equity of 10.51% and a net margin of 1.17%.CVS Health’s revenue was up 8.4% on a year-over-year basis. During the same period in the previous year, the company posted $1.83 EPS. CVS Health has set its FY 2025 guidance at 6.300-6.400 EPS. Analysts expect that CVS Health Corporation will post 5.89 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, November 3rd. Stockholders of record on Thursday, October 23rd will be given a $0.665 dividend. This represents a $2.66 annualized dividend and a dividend yield of 3.5%. The ex-dividend date of this dividend is Thursday, October 23rd. CVS Health’s payout ratio is presently 74.30%.

Insider Activity at CVS Health

In other news, Director Anne A. Finucane sold 7,500 shares of the business’s stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $71.02, for a total value of $532,650.00. Following the completion of the transaction, the director directly owned 22,156 shares of the company’s stock, valued at approximately $1,573,519.12. The trade was a 25.29% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 1.22% of the company’s stock.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.